Liothyronine sodium - Thyrotoxicosis

You are here : Home > Formulary Search > Liothyronine sodium - Thyrotoxicosis

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Red

Formulations :

Capsules

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Associated Icons :

BNF SPC

Restrictions / Comments :

Documentation

Evidence Review

Liothyronine CAPSULES - APC briefing paper - March 2022

Patient resource

Liothyronine caps - Patient Information - April 2022.pdf

Miscellaneous

SDCCG - Low value medicines implementation resources - Apr 2018

PAD Profile

ChemicalSubstance :

Liothyronine sodium

Indication :

Thyrotoxicosis

Group Name :

Keywords :

Hypothyroidism, underactive thyroid,L-T3, L-Tri-iodothyronine sodium, low value medicines, drugs of low clinical value, LVM, drugs of limited clinical value

Brand Names Include :

Important Information :

Latest Additions Date From :

Latest Additions Date To :

Guidelines :

Supporting Documents :

Other Indications

Below are listed other indications that Liothyronine sodium is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Thyrotoxicosis.

No records returned.

Committee Recommendations (1)

06 Apr 22 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

In March 2016 the APC (formerly PCN) agreed liothyronine (T3) as an option in the management of hypothyroid states occuring in the treatment of thyrotoxicosis and assigned it a RED traffic light status for this indication.

Licensed, bioequivalent liothyronine CAPSULES have entered the market at a considerably reduced price and the APC recommend that:

- the most cost effective preparation should be prescribed (currently capsules) in all new patients
- prescribers should consider switching existing patients from tablets to capsules - for discussion with the patient at next review

The APC noted the additional information provided in the Liothyronine capsules - briefing paper below